GSK grabs new drug development head from Boehringer
LONDON: GlaxoSmithKline has hired Chris Corsico from German drugmaker Boehringer Ingelheim to fill the new role of senior vice-president development as the company reshapes its research strategy, a spokesman for the British group said.
Corsico, currently chief medical officer at Boehringer, will start at GSK on January 1, reporting to research head Hal Barron.
Barron himself joined GSK at the start of 2018 in a key appointment for new Chief Executive Emma Walmsley, whose top priority is to improve research productivity in pharmaceuticals.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd